Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: 2 | History Defined

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

On Wednesday, Amgen Inc. (NASDAQ:AMGN) and its partner Zai Lab (NASDAQ:ZLAB) said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed.

Benzinga

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Argenx SE (NASDAQ:ARGX) stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab).

Benzinga

CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential

CareDx, Inc. (NASDAQ:CDNA) faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company’s expanding transplant solutions platform positions it for long-term opportunity in an $8 billion market.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

As Zero-Emission Credit Revenue Dries Up, What Does That Mean for Tesla Stock?

As Tesla loses its regulatory credit revenue stream, the company now faces growing pressure to sustain profitability through core operations amid cooling EV demand and intensifying competition.

Barchart

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

The biotechnology sector is experiencing a surge in innovation as companies develop advanced therapies to address complex diseases. This wave of progress is particularly evident in the development of novel treatments for autoimmune disorders, where cutting-edge cell therapies hold promise to transform patient care.

Benzinga

Thermo Fisher Positioned As Biopharma's Partner Of Choice

Could Thermo Fisher Scientific Inc. (NYSE:TMO) be the unsung hero of the biopharma sector's future? While its stock performance has recently lagged, analysts are betting on a major turnaround driven by strategic acquisitions and robust growth potential. William Blair initiated coverage on Tuesday on Thermo Fisher Scientific, citing a strong…

Benzinga

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Investors appear disappointed with Viking Therapeutics Inc.’s (NASDAQ:VKTX) data from its Phase 2 trial of an obesity pill.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

As SoFi Launches International Money Transfer Services, How Should You Play SOFI Stock?

SoFi Technologies announced plans to launch an international money transfer service by the end of 2025. Here’s why that could prove a major positive for SOFI stock.

Barchart

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and…

Benzinga

Analysts Love This AI Data Center Stock

This data center stock has just received an ‘Outperform’ rating from a major financial firm after posting its quarterly results.

Barchart

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.

Benzinga

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Benzinga

IDEXX Surpasses Earnings Expectations, Justifying Premium Valuation

Pet healthcare is witnessing a surge in demand as more households prioritize their pets’ well-being, driving companies in this sector to outperform expectations. This trend is reflected in IDEXX Laboratories Inc.‘s (NASDAQ:IDXX) recent financial results, showcasing significant growth and revised earnings guidance.

Benzinga

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Trump Won’t Take Away Tesla’s Subsidies. Does That Make TSLA Stock a Safe Buy Here?

Despite Trump’s reassurance that he won’t strip Tesla of its subsidies, his tax bill has already hurt the company, raising questions about whether TSLA stock remains a safe investment.

Benzinga

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncology, Inc. (NASDAQ:CRDF) on Tuesday released data from the ongoing CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in…

Benzinga

AI-Focused Waystar, Iodine Deal Wins Praise For Margin Upside

Waystar Holding (NASDAQ:WAY) on Wednesday agreed to acquire Iodine Software from shareholders led by Advent International, a private equity firm, for a total of $1.25 billion.

Benzinga

Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks

Quest Diagnostics Inc. (NYSE:DGX) delivered a robust second quarter in 2025, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Sarepta's Setback Deepens With Another Gene Therapy Fatality

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company’s recent efforts to provide clarity on its restructuring and FDA label plans.

Barchart

Tesla’s Q2 Earnings Will Likely Focus on Politics and Robotaxis, But Investors Should Really Watch for These 5 Things

Tesla will release its Q2 2025 earnings next week. While AI and CEO Elon Musk’s politics might take center stage, there are some other pressing issues that the company should address.

Benzinga

Medtronic Stock Is Climbing Friday: What's Going On?

On Wednesday, the Centers for Medicare Medicaid Services (CMS) proposed a significant step toward broader adoption of renal denervation (RDN) by offering coverage for both radiofrequency (rfRDN) and ultrasound (uRDN) technologies for uncontrolled hypertension. This coverage would be granted under a Coverage with Evidence Development (CED) framework, requiring treatment within…

Barchart

Elon Musk Launches the America Party. How Should You Play Tesla Stock Here?

Tesla stock lost nearly 7% Monday after Elon Musk announced plans of launching the “America Party.” William Blair downgraded TSLA shares.

Barchart

Can Oklo Stock Hit $75 in 2025?

Wedbush analysts have an ambitious price target of $75 on Oklo’s stock.

The Independent UK

From In-N-Out to McDonald’s: The restaurant chains with the highest and lowest employee satisfaction scores revealed

91 percent of In-N-Out employees said they’d recommend their jobs to a friend

Barchart

Elon Musk’s ‘KILL the BILL’ Sends Tesla Shares Down. Is It Time to Sell TSLA Stock Here?

Tesla shares crater as President Donald Trump says he’s disappointed in Elon Musk. A William Blair analyst remains bullish on TSLA stock.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.